Lilly showcases retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026
- TRIUMPH‑4 (68 weeks) reported retatrutide reduced WOMAC knee pain by up to 4.5 points (75.8%) from a baseline of 6.0, with more than 1 in 8 patients pain‑free at trial end.
- TRIUMPH‑1 (80 weeks) reported retatrutide reduced WOMAC knee pain by up to 4.3 points (73.1%) from a baseline of 6.0, with more than 1 in 6 patients pain‑free.
- TOGETHER‑PsA (52 weeks) showed ixekizumab plus tirzepatide achieved ACR50 in 43.7% of patients versus 15.7% for ixekizumab alone, with incremental improvement after week 36.
- Retatrutide is an investigational once‑weekly triple GIP/GLP‑1/glucagon receptor agonist; tirzepatide is a dual GIP/GLP‑1 agonist; ixekizumab selectively inhibits IL‑17A.
Conference context
Eli Lilly will present clinical and real‑world data at ACR Convergence 2026 (Nov 6–11) on treatments addressing the intersection of rheumatologic disease and obesity, citing the high prevalence of overweight/obesity in these populations (≈80% for knee osteoarthritis; ≈65% for psoriatic arthritis in the U.S.).
Retatrutide: knee osteoarthritis trials
Phase 3 TRIUMPH trials reported substantial reductions in knee pain measured by the WOMAC pain subscale. In TRIUMPH‑4 (68 weeks) retatrutide reduced pain by up to 4.5 points (75.8%) from a baseline of 6.0, with >1 in 8 treated patients recording no knee pain at trial end. In TRIUMPH‑1 (80 weeks) reductions reached 4.3 points (73.1%) with >1 in 6 treated patients pain‑free.
Taltz plus Zepbound in psoriatic arthritis
Detailed 52‑week results from the TOGETHER‑PsA study showed ixekizumab (Taltz) plus tirzepatide (Zepbound) produced greater disease control, patient‑reported and metabolic outcomes versus ixekizumab alone. ACR50 was 43.7% with the combination compared with 15.7% for ixekizumab monotherapy, with further gains evident after Week 36.
Additional programme highlights
Presentations include a retatrutide plenary (Nov 8) and an oral presentation of TOGETHER‑PsA one‑year data (Nov 11), plus posters and real‑world and modelling studies on concomitant ixekizumab/tirzepatide use, cardiovascular risk factor changes, early disease control, and economic outcomes.
Source: Lilly